Three AML samples with Npm1 mutations (#7–9, Table 1), which had shown mixed engraftment in previous experiments, and from which sufficient primary material was still available were chosen to elucidate the origin of engrafted human myeloid and lymphoid cell types (CD33+, CD3+ and CD19+). This evidence concerns the gene CD33 and acute myeloid leukemia.